logo BDSP

Base documentaire

  1. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.

    Article - En anglais


    The American Thoracic Society (ATS) published guidelines based on expert opinion and published data-but not clinically derived or validated-for treating adult outpatients with community-acquired pneumonia.


    - To compare medical outcomes and antimicrobial costs for patients whose antimicrobial therapy was consistent or inconsistent with ATS guidelines.


    - Multicenter, prospective cohort study.


    - Emergency departments, medical clinics, and practitioner offices affiliated with 3 university hospitals, 1 community teaching hospital, and 1 health maintenance organization.


    - A total of 864 immunocompetent, adult outpatients with community-acquired pneumonia : 546 aged 60 years or younger with no comorbidity and 318 older than 60 years or with 1 comorbidity or more.

    Main Outcome Measures

    - Patients'antimicrobial therapy was classified as being consistent or inconsistent with the ATS guidelines.

    Mortality, subsequent hospitalization, medical complications, symptom resolution, return to work and usual activities, health-related quality of life, and antimicrobial costs were compared among those treated consistently or inconsistently with the guidelines.


    - Outpatients aged 60 years or younger with no comorbidity who were prescribed therapy consistent with ATS guidelines (ie, erythromycin with some exceptions) had 3-fold lower antimicrobial costs ($5.43 vs $18.51 ; P<. (...)

    Mots-clés Pascal : Pneumonie, Infection communautaire, Etude cohorte, Antimicrobien, Coût, Traitement, Immunocompétence, Indication, Evaluation, Homme, Appareil respiratoire pathologie, Poumon pathologie, Organisation santé, Immunopathologie, Bactériose, Infection, Chimiothérapie, Immunodéficit, American Thoracic Society Guidelines

    Mots-clés Pascal anglais : Pneumonia, Community acquired infection, Cohort study, Antimicrobial agent, Costs, Treatment, Immunocompetence, Indication, Evaluation, Human, Respiratory disease, Lung disease, Public health organization, Immunopathology, Bacteriosis, Infection, Chemotherapy, Immune deficiency

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0381072

    Code Inist : 002B11D. Création : 12/09/1997.